Skip to main content
ALLR
NASDAQ Life Sciences

Allarity Settles $4.9M Novartis Liability for $1M; Books First CLIA Lab Contract

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.842
Mkt Cap
$13.849M
52W Low
$0.769
52W High
$1.84
52W Position info
9.5% above low
Off High info
54% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

ALLR is trading near its 52-week low of $0.769 (9.5% above the low).

Summary

Allarity settled a $4.9 million Novartis liability for $1 million in cash and announced its first revenue-generating contract under its new CLIA lab services strategy. The settlement removes a large balance-sheet obligation; the contract's value was not disclosed.


Key Events · Legal and Risk Events · ALLR

  • Novartis Liability Settled at Deep Discount

    Allarity will pay Novartis $1,000,000 in cash to fully discharge an aggregate liability of $4,900,000 plus interest, extinguishing roughly $3.9 million of obligations before interest.

  • Mutual Releases on Payment

    Upon receipt of the $1,000,000, Novartis releases Allarity and affiliates from all claims tied to the liability, and Allarity releases Novartis, except for claims enforcing the settlement itself.

  • First CLIA Lab Services Contract

    Allarity signed its first revenue-generating contract under its CLIA-certified laboratory services strategy, providing development and validation services for a European biotech's precision oncology predictive device for U.S. use. No contract value was disclosed.

  • Stenoparib Still the Priority

    Management stated stenoparib remains the company's top development priority, with the lab services agreement positioned as incremental revenue from existing capabilities.


Analysis · ALLR · Life Sciences

For a company with a small market cap, Allarity wiped out a $4.9 million-plus-interest liability to Novartis for a single $1 million cash payment, extinguishing roughly $3.9 million of obligations and the associated legal overhang. Separately, the company signed its first revenue-generating contract under its CLIA-certified lab services strategy, providing development and validation work for a European biotech's precision oncology device aimed at the U.S. market. No dollar value for that contract was disclosed, so the near-term revenue contribution is unknown, but it is the first commercial validation of a business line the company has been building since receiving CLIA certification in July 2026. Stenoparib remains the top development priority.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ALLR was trading at $0.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.8M. The 52-week trading range was $0.77 to $1.84. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ALLR - Latest Insights

ALLR
Nov 17, 2026, 7:50 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.870
Real-time Price: $0.830 info
Change: -$0.040 (-5%) info
Market Cap: $13.454M info
ALLR
Nov 13, 2026, 8:07 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $0.950
Real-time Price: $0.830 info
Change: -$0.120 (-13%) info
Market Cap: $13.454M info
ALLR
Nov 13, 2026, 8:05 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.950
Real-time Price: $0.830 info
Change: -$0.120 (-13%) info
Market Cap: $13.454M info
ALLR
Oct 30, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.870
Real-time Price: $0.830 info
Change: -$0.040 (-5%) info
Market Cap: $13.454M info
ALLR
Sep 14, 2026, 12:14 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.21
Real-time Price: $0.830 info
Change: -$0.380 (-31%) info
Market Cap: $13.454M info